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Diabetes mellitus has existed for at least 2000 years and has been treated with 
materials derived from plants in many cultures of the world. The mengkudu 
(Morinda cUrl/olia) are known for countless medicinal values and the ripe fruits 
were being used traditionally in Malaysia for the treatment for diabetes mellitus. This 
study was carried out to verify the hypoglycaemic property and its possible effect on 
insulin secretion. Freeze-dried aqueous extracts of various doses of3mglkg, 30mglkg 
and 300mglkg were administered to normal rats in an acute effect study and the 
doses of 3mglkg, 3Omglkg, 300mglkg, 60Omglkg, 900mglkg and 1200mglkg were 
administered to streptozotocin induced type 2 diabetic rats in a chronic effect study 
in an Oral Glucose Tolerance Test (OGTI). Results from the choric effect study 
showed that the 300mglkg dose treated rats had an apparent hypoglycaemic effect as 
evident from the blood glucose level measured as the area under the OGTT curve 
(AUe: 4370.70 ± 99.13 mgo/omin) after 6 weeks of oral administration. 
Hypoglycaemic activity was also observed in the 600mglkg dose after 5 weeks of 
oral administration (AUe: 4486.70 ± 35.60 mgo/omin), the 900mglkg dose after 4 
weeks of oral administration (AUe: 4340.40 ± 72.90 mg%min) and the 1200mglkg 
dose after 4 weeks of oral administration (AUe: 4554.00 ± 49.80 mg%min). All the 
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Ave values were significantly lower compared to control. The aqueous extracts 
were also able' to impede the rate of glucose increase and enhance the glucose 
clearance. However, the results from the insulin assay did not show any significant 
change in the insulin release profile as compared to control. As a conclusion, the 
aqueous extract of mengkudu (Morlnda eim/olia) fruit preparations in the doses of 
30Omglkg, 6OOmg/kg, 90Omg/kg and 1200mglkg might contain plant compounds 
that have substantial hypoglycemic property only in the chronic effect study but did 
not affect the insulin secretion in the type 2 diabetic rats. Future studies should be 
carried out in order to further discover its mechanisms of action, isolation and 
identification of the hypoglycaemic components particularly with regard to the 
healing of diabetes by means of plant resources. 
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Penyakit diabetes mellitus telah dikesan semenjak 2000 tahun dahulu dan eara 
rawatannya dengan menggunakan tumbuhan telah dikenalpasti di pelbagai 
kebudayaan di merata dunia. Mengkudu (Morinda citrifolia) amat terkenal dengan 
pelbagai nilai perubatan dan telah digunakan seeara tradisional untuk merawat 
diabetes mellitus di Malaysia. Objektif eksperimen ini ialah untuk membuktikan 
kesan bipoglisemik dan kesannya terhadap perembesan hormon insulin. Ekstrak buah 
berakua yang telah disejukbekukan telah diberikan kepada tikus normal (3mglkg, 
30mglkg dan 30Omglkg) untuk kajian kesan akut dan tikus diabetik jenis 2 (3mglkg, 
30mglkg, 300mglkg, 60Omglkg, 9OOmg/kg dan 1200mg/kg) untuk kajian kesan 
kronik di dalam Ujian Toleransi Glukosa. Keputusan kajian kesan kronik 
menunjukkan bahawa tikus kajian yang diberikan dos 300mg/kg mempunyai aras 
glukosa darah yang lebih rendah berdasarkan nilai keluasan dibawah graf (AUC: 
4370.70 ± 99.13 mg%min) setelah rawatan oral selama 5 minggu. Kesan 
bipoglisemik juga diperhatikan untuk dos 600mglkg selepas rawatan 5 minggu 
(AUe: 4486.70 ± 35.60 mgo/omin), dos 900mg/kg selepas rawatan 4 minggu (AUC: 
4340.40 ± 72.90 mg'l/omin) dan dos 1200mg/kg juga selepas 4 minggu rawatan 
(AUe: 4554.00 ± 49.80 mgolomin). Kesemua nilai keluasan di bawah graf (AUC) 
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adalah lebih rendah berbanding dengan kumpulan kawalan .. Ekstrak berakua tersebut 
juga berupaya untuk merendahkan kadar peningkatan glukosa darah dan 
mempercepatkan kadar penghapusan glukosa d.arah. Walau bagairnanapun, 
keputusan ujian am insulin menunjukkan bahawa ekstrak tersebut tidak 
mempengaruhi corak perembesan harmon insulin. Sebagai kesimpulan ekstrak 
berakua buah menglrudu (Monnda citrifolia) berdos 300mglkg, 60Omglkg, 
900mglkg dan 1200mglkg berupaya untuk merendahkan aras glukosa darah tikus 
diabetik jenis 2 di dalam kajian kronik sahaja dan tidak mempengarnhi perembesan 
hormon insulin. Berdasarkan kepada keputusan iDL kajian lanjutan masih perlu 
dilakukan untuk mengkaji mekanisme tindakannya, pengasmgan dan 
pengenalpastian komponen-komponen bipoglisemik di da1am eksttak tersebut 
seiringan dengan kajian 1D1tuk rawatan diabetes mellitus dengan menggunakan 
sumber tumbuhan tempatan. 
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CHAPTERl 
INTRODUCTION 
Diabetes mellitus is currently a major global issue in public health. The 
occurrence and prevalence of this disease are alanningly escalating in developing and 
newly industrialized countries (King, 1993). The prevalence of diabetes worldwide was 
estimated to be 4% (135 million people) in 1995 and to increase to 5.4% (estimated 300 
million people) by the year 2025 (King et aI., 1998.) 
The World Health Organization (WHO) bas recognized 2 major clinical forms of 
diabetes mellitus, namely Insulin-Dependant Diabetes Mellitus (lDDM) or Type 1 
Diabetes Mellitus and Non-Insulin-Dependent Diabetes Mellitus (NIDDM) or Type 2 
Diabetes Mellitus. About 9C)OA, of all cases of diabetes in developed and developing 
countries are NIDDM, primarily found in adult of more than 30 years old (WHO Study 
Group, 1994). 
Asia faces the greatest threat of an epidemic of NIDDM. In 1994, over 43 
million people in Southern, Southeast and East Asia were estimated to have NIDDM. 
WHO has recognized that Asia as having a potential increase with 2.5 to 3 times more 
common diabetes than the situation today. Hence by the year 201 0, Asia is estimated to 
have 138 million diabetic patients (Amos et aI., 1997). 
21 
In Malaysia, diabetes is a growing concern among the population especially the 
government and health practitioners. Throughout the six years Healthy lifestyle 
Campaign by the Ministry of Hea.lth, which started in 1991, diabetes mellitus became 
the theme for the year 1995. Tn 1986, the prevalence of the disease in Peninsular 
Malaysia as reported in the First National Health and Morbidity Survey was 6.3% and in 
1995, the Cardiovascular Unit in the Department of Public Health, Ministry of Health 
... 
reported that the prevalence to at 7.7010. The prevalence seemed to be on the rise. 
Recognizing diabetes as a growing public health problem in Malaysia, a scope on 
diabetes was introduced in the Second National Health and Morbidity Survey (NHMS2). 
It was carried out to provide a comparative picture of the epidemiology of diabetes 
mellitus in the population of Malaysia within the last ten years since 1986. In 1997, the 
survey reported that the national prevalence was found to be 8.3% in the population of 
age 30 years and above. (Ministry of Health, 1999) 
The highest occurrence of identified diabetics by ethnicity was amongst Indians 
(11.5%) and they were considerably higher than other ethnic groups. The prevalence 
amid Chinese was 6.3% and Malays was 5.2% whilst other Bmniputera had significantly 
lower prevalence 2.7%. The prevalence of known diabetics by gender showed that males 
reported to have higher prevalence (5.9%) compared to females (5.8%)(Ministry of 
Health, 1999). 
Undiagnosed diabetes was defined as whole blood capillary glucose level of 
equal or more that 11.1 mmoll1 among those who did not report themselves as known 
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diabetics. From the survey, the national prevalence of undiagnosed diabetics was 2.5%. 
By ethriicity, Indians had the highest prevalence of undiagnosed diabetics, which was 
3.4% and by gender� females recorded higher prevalence (2.6%) than males 
(2.5%)(Ministry of Health, 1999). 
In Malaysia, a number of reported death cases from the Ministry of Health 
(1999) were related to heart disease, stroke or chronic renal failure, some of which might 
be associated to diabetes. It is projected that the number of diabetics will be rising from 
418,000 cases in 1994 to 810,000 cases and 1,201,000 estimated cases in year 2000 and 
2010 respectively (Ministry of Health, 1999) 
The Ministry of Health in Malaysia has reported that in 1994, about 4.3% of 
diabetic patients seek treatment in private and government hospitals and about 0.9% 
seeks treatment in traditional medicine practitioner (Ministry of Health, 1995). Even 
today, the practice of various traditional medicinal systems are still flourishing in 
different countries and among different ethnic groups and nearly 80% of the rural 
population still depend on plant based medicines (Sasson, 1996). About 80% of the rural 
population in many tropical developing countries still depends on traditional 
practitioners for their health care, which means that the community has to rely on 
medicinal plants for treatment (Farnsworth, 1983). 
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The traditional method of treating diabetes is yet to be explored; Malaysia is 
richly endowed with diverse flora with good potential to be developed into various 
useful natural products (Soepadmo, 1993). Our country is known to have a large amount 
of plant species and a number of them have been traditionally used to treat many disease 
and ailments. Similar to other diseases, diabetes mellitus has been treated traditionally 
by oral consumption of plant extracts based on folk and traditional cures since ancient 
times (Ajgoankar, 1979). 
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